BioMedNewsBreaks

WednesdaySep 23, 2026 11:53 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO)(OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF) Awarded Digital Health Innovation Fund Grant for AI-Driven Oncology Platform 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) and Redwood AI (CSE: AIRX) (OTCQB: RDWCF), together with Canada's Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, were awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute to support development of Onco SynoGraph AI-driven oncology platform. The reimbursement-based grant covers up to 25% of an estimated $3.5 million project budget. The project will advance SynoGraph using federated learning and causal AI to…

Continue Reading

WednesdaySep 23, 2026 9:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar

Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, which will cover OMAI market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships and contribution to shareholder value. OMAI core capabilities and initial platform were developed within Lantern clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is expanding into additional diseases, therapy…

Continue Reading

TuesdaySep 22, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma ("MCL"), double-hit lymphoma ("DHL") and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern existing composition-of-matter patent estate. Lantern Pharma (NASDAQ: LTRN) is evaluating LP-284 in an ongoing Phase 1a…

Continue Reading

FridaySep 18, 2026 3:45 pm

BioMedNewsBreaks — Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Aligns Manufacturing, Preclinical Work and Clinical Planning for ONC010

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by bringing together drug manufacturing, nanoparticle formulation, analytical development, preclinical studies and regulatory planning. ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation, with the broader strategy focused on disrupting cancer cells’ DNA repair mechanisms and potentially enhancing the effects of radiation and certain chemotherapy treatments. The company has completed a 300-gram development batch of A83B4C63 at approximately…

Continue Reading

FridaySep 18, 2026 3:13 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Is Building End-to-End Platform for the Future of Medical Imaging

Nanox (NASDAQ: NNOX) is positioning itself as an integrated medical imaging and healthcare technology company, combining proprietary digital X-ray hardware, FDA-cleared AI applications, cloud software, teleradiology, and healthcare IT into an end-to-end platform designed to support earlier disease detection and more efficient care. Its ecosystem includes Nanox.ARC and the next-generation Nanox.ARC X imaging systems, Nanox.AI algorithms for identifying potential signs of chronic disease, Nanox.CLOUD for imaging management, and services through USARAD, Nanox.MARKETPLACE and Nanox Health IT. The company is expanding commercial and clinical activity through relationships with organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital, while also…

Continue Reading

FridaySep 18, 2026 11:10 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) CEO Discusses GelrinC(R), U.S. Pivotal Study and European Commercialization on BioMedWire Podcast

Regentis Biomaterials (NYSE American: RGNT) Executive Chairman and CEO Dr. Ehud Geller joined the latest episode of The BioMedWire Podcast to discuss the company regenerative medicine platform and lead product GelrinC(R), which is being developed to treat cartilage injuries in the knee. Geller said GelrinC(R) is approved for marketing in Europe and is undergoing a U.S. pivotal clinical trial, with Regentis working to expand clinical sites and complete enrollment around year-end. He also discussed a U.S. market estimated at 470,000 currently untreated cases annually and the company efforts to advance European commercialization through discussions with distribution systems and major orthopedic…

Continue Reading

ThursdaySep 17, 2026 2:36 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Into Pivotal Stage of Development

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, an off-the-shelf hydrogel implant designed to support the body’s natural regeneration of damaged knee cartilage. Delivered as a liquid and cured in place with UV light, GelrinC forms a temporary scaffold that gradually degrades over roughly six to nine months, creating an environment intended to support the development of new cartilage without requiring cell harvesting or laboratory expansion. The company cites encouraging Phase 2 data from 56 patients, including improvements in pain and function through four years of follow-up, and says imaging has…

Continue Reading

ThursdaySep 17, 2026 11:41 am

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap 

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar Sept. 23 at 12:30 p.m. Eastern to present the business model, development roadmap and value proposition of Open-Medicine AI ("OMAI"), its wholly owned subsidiary developing a multi-agentic AI platform for end-to-end therapeutic development. The session, led by Panna Sharma, founder and CEO of Open-Medicine AI, will cover OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities and its planned subscription and enterprise licensing business model. To view the full press release, visit https://ibn.fm/MQ8Mc…

Continue Reading

ThursdaySep 17, 2026 11:31 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and a $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report. To view the full press release, visit https://ibn.fm/WNsHM About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

Continue Reading

ThursdaySep 17, 2026 11:22 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project 

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique - Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker. DETECSEPS will evaluate an early detection approach combining a routinely used clinical score with Volition’s Nu.Q NETs H3.1 blood…

Continue Reading